Literature DB >> 6139572

Vasoactive intestinal peptide causes bronchodilatation and protects against histamine-induced bronchoconstriction in asthmatic subjects.

A Morice, R J Unwin, P S Sever.   

Abstract

Vasoactive intestinal peptide (VIP) caused significant bronchodilatation in seven asthmatic volunteers when given intravenously at the rate of 6 pmol/kg/min for 15 min during a double-blind study. Tachycardia and cutaneous flushing were observed during the infusion. VIP also ameliorated histamine-induced bronchoconstriction in all subjects. VIP may be an important natural bronchodilator in man and this has implications for the pharmacotherapy of asthma.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6139572     DOI： 10.1016/s0140-6736(83)91272-2

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


  16 in total

1.  High-mobility group box 1: a novel target for treatment of Pseudomonas aeruginosa keratitis.

Authors:  Sharon McClellan; Xiaoyu Jiang; Ronald Barrett; Linda D Hazlett
Journal:  J Immunol       Date:  2015-01-14       Impact factor: 5.422

2.  Effect of peptide histidine valine on cardiovascular and respiratory function in normal subjects.

Authors:  E R Chilvers; C M Dixon; Y Yiangou; S R Bloom; P W Ind
Journal:  Thorax       Date:  1988-10       Impact factor: 9.139

3.  Regulatory peptides in the respiratory system.

Authors:  P J Barnes
Journal:  Experientia       Date:  1987-07-15

4.  The third nervous system in the lung: physiology and clinical perspectives.

Authors:  P J Barnes
Journal:  Thorax       Date:  1984-08       Impact factor: 9.139

Review 5.  The neuropeptide vasoactive intestinal peptide: direct effects on immune cells and involvement in inflammatory and autoimmune diseases.

Authors:  D Ganea; K M Hooper; W Kong
Journal:  Acta Physiol (Oxf)       Date:  2014-12-11       Impact factor: 6.311

6.  Pulmonary clearance of vasoactive intestinal peptide.

Authors:  M P Barrowcliffe; A Morice; J G Jones; P S Sever
Journal:  Thorax       Date:  1986-02       Impact factor: 9.139

7.  VIP antagonists enhance excitatory cholinergic neurotransmission in the human airway.

Authors:  H Aizawa; H Inoue; M Shigyo; S Takata; H Koto; K Matsumoto; N Hara
Journal:  Lung       Date:  1994       Impact factor: 2.584

Review 8.  Structure-activity relationship of vasoactive intestinal peptide (VIP): potent agonists and potential clinical applications.

Authors:  Satomi Onoue; Shingen Misaka; Shizuo Yamada
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-01-03       Impact factor: 3.000

9.  A comparison of the ventilatory, cardiovascular and metabolic effects of salbutamol, aminophylline and vasoactive intestinal peptide in normal subjects.

Authors:  A H Morice; P Schofield; E E Keal; P S Sever
Journal:  Br J Clin Pharmacol       Date:  1986-08       Impact factor: 4.335

Review 10.  Neuroendocrine cells derived chemokine vasoactive intestinal polypeptide (VIP) in allergic diseases.

Authors:  Alok K Verma; Murli Manohar; Sathisha Upparahalli Venkateshaiah; Anil Mishra
Journal:  Cytokine Growth Factor Rev       Date:  2017-09-23       Impact factor: 7.638
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.